A Phase III Randomized Trial Comparing Adjuvant MK- 3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma

IRB/UVA Tracking #

21435

Contact

Rachael Reed

Contact Email

rmr3bx@hscmail.mcc.virginia.edu

Contact Phone

Phase

III

Primary purpose

Treatment

NCT

Cancer PI

Elizabeth M Gaughan

Status

OPEN TO ACCRUAL

Ages

Adult